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The effect of oral anticoagulation on clotting during hemodialysis
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The effect of oral anticoagulation on clotting during
hemodialysis.
Background. Between 5% and 10% of hemodialysis pa-
tients are treated with oral anticoagulants. It is currently
unknown whether additional anticoagulation with heparin or
low-molecular-weight heparin (LMWH) is needed to prevent
clotting during hemodialysis.
Methods. In this prospective, randomized, cross-over study
10 patients treated with oral anticoagulants (phenprocoumon)
received either no additional anticoagulation or low dose dal-
teparin (bolus of 40 IU/kg body weight) before dialysis. Efficacy
of hemodialysis was measured by normalized weekly Kt/V and
urea reduction rate (URR). Thrombus formation was evalu-
ated by measurement of D-dimer and inspection of air traps
and dialyser.
Results. The median international normalized ratio (INR) did
not differ between both observation periods (phenprocoumon
2.2(2 to 3) vs. dalteparin 2.1(2 to 2.9). The anti-Xa level in dal-
teparin patients was 0.33 (0.27 to 0.38) IU/mL after 2 hours
and 0.16 (0.03 to 0.23) IU/mL after 4 hours of hemodialysis.
The median increase of D-dimer was significantly higher in pa-
tients without additional dalteparin therapy during hemodial-
ysis (D-dimer 0.23 lg/mL vs. 0.03 lg/mL) (P = 0.0004).
Complete thrombosis of the dialyser membrane occurred in
one patient in the phenprocoumon group but in none with com-
bined treatment. The extent of thrombosis in the arterial and
venous air trap and dialyser was significantly less in patients
with additional dalteparin therapy (P = 0.0014, P = 0.0002, and
P = 0.0005, respectively). Weekly Kt/V and URR was similar
in both groups.
Conclusion. Standard oral anticoagulation with an INR be-
tween 2 and 3 is insufficient to prevent clotting during hemodial-
ysis. Additional low dose anticoagulation with a LMWH or
heparin is necessary to facilitate treatment.
Patients with end-stage renal disease (ESRD) have a
clearly increased risk of bleeding caused by anticoagula-
tion with heparin during hemodialysis, uremia-associated
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platelet dysfunction, and other defects of haemostasis.
Hemorrhages occur with a frequency of 0.1 events/patient
year and increase by a factor of 2.4 with the additional
intake of oral anticoagulants [1]. In particular cerebrovas-
cular events, which have a mortality rate of 70%, can be
seen frequently [2]. However, in certain settings oral an-
ticoagulation is mandatory. Hemodialysis patients with
atrial fibrillation have a 30% risk of thromboembolic
events per year [3]. Similarly the risk of thrombosis or
thromboembolic events outweighs the risk of bleeding
in patients with prosthetic heart valves [4] or the phos-
pholipid antibody syndrome [5], thus currently approxi-
mately 6% of dialysis patients are treated with oral anti-
coagulants [6].
It is hitherto unknown whether standard oral antico-
agulation might be sufficient to prevent clotting during
hemodialysis or if additional administration of a low-
molecular-weight heparin (LMWH) or unfractionated
heparin is necessary. Data in other settings seem to both
support and contradict an equipotent efficacy of oral an-
ticoagulation and heparins. In patients with prosthetic
heart valves for example, intermittent interruption of oral
anticoagulation can be bridged with a LMWH. A dose
leading to a peak anti-Xa level of 0.2 to 0.6 IU/mL seems
to be sufficient and might thus be equivalent to an in-
ternational normalized ratio (INR) of 2.5 to 3.5 [4]. On
the other hand, LMWH therapy seems to be superior
to oral anticoagulation in perioperative prophylaxis of
deep vein thrombosis after hip or knee replacement [7],
or secondary prevention of venous thromboembolism in
patients with cancer [8, 9]. This superiority seems not to
be related to the dose administered, since both high doses
(enoxaparin 1.5 mg/kg body weight and dalteparin 150 to
200 IU/kg body weight) as well as lower doses (enoxa-
parin 2 × 30 mg/day) are more effective than warfarin
sodium with a target INR of 2 to 3 [9]. Regarding these
differing results it seems to be impossible to relate a spe-
cific INR to an equipotent level of anti-Xa or prolonged
activated partial thromboplastin time (aPTT). Thus, on
one hand an INR sufficient to prevent most throm-
boembolic complications could also be sufficient for the
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prevention of thrombosis during hemodialysis. On the
other hand, however, the specific situation of hemodial-
ysis, with activation of the clotting cascade by an extra-
corporeal membrane, might incur the necessity of a more
aggressive anticoagulation.
In order to clarify the need of an additional antico-
agulation during hemodialysis in patients with phenpro-
coumon therapy this prospective, randomized, cross-over
study was undertaken.
METHODS
Study design
Two centers, the Department of Internal Medicine III,
Division of Nephrology and Dialysis, University Hospital
Vienna, and the Department of Nephrology and Dialy-
sis, Wilhelminenspital Vienna, took part in this prospec-
tive, randomized, cross-over study. Ten patients with
oral anticoagulation (phenprocoumon) on maintenance
hemodialysis (mean ± SD 11 ± 6 months) were enrolled
in the study. The patients were randomized to either no
additional anticoagulation during hemodialysis or to ad-
ditional low dose dalteparin (40 IU/kg body weight) for
1 week (i.e., three hemodialysis sessions). During the suc-
cessive second week the opposite treatment was admin-
istered. Thus each patient was treated with and without
additional dalteparin for 1 week. In order to achieve an
anti-FXa serum level greater than 0.4 IU/mL after 4 hours
of dialyis, which is recommended to prevent clotting [10],
a dalteparin dose of approximately 70 IU/kg body weight
is necessary. At our institution we use a slightly higher
standard dose of 80 IU/kg body weight. In patients treated
with warfarin, however, the dose can be reduced to at
least 40 IU/kg body weight [10].
The study protocol was approved by the Ethical Com-
mittee of the University Vienna, and the patients had to
give informed consent before inclusion.
Patients
Phenprocoumon was administered due to chronic
atrial fibrillation (N = 7), recurrent thrombosis of arteri-
ovenous fistula (N = 1), deep vein thrombosis (N = 1),
and superior caval vein obstruction (N = 1). The dialysis
sessions lasted for 4 hours in eight patients and for 31/2
hours in two patients. The individual treatment time was
not changed between the study periods. The vascular ac-
cess was an arteriovenous fistula (Cimino shunt) in seven
patients, vascular transposition (one each right upper and
lower arm) in two and Grazc‘sche fistula (cubital) in one.
Dialysis procedures
Hemodialysis was performed using standard dialysis
solutions. Standard bicarbonate concentrations were ad-
justed if necessary (in one patient adjusted to 34 mmol/L,
in two adjusted to 36 mmol/L). The dialyzer membranes
were either polysulfone/polyarylethersulfone or modi-
fied cuprophan membranes (FX10) (Fresenius Medical
Care, Bad Homburg, Germany) (1050MD) (Asahi Medi-
cal, Tokyo, Japan) (Arylane H9) (Gambro Hospal Indus-
trie, Meyzien, France) (FB-210U) (Nipro Corporation,
Osaka, Japan). Both polysulfone membranes as well as
cellulose triacetate membranes are biocompatible and
have a similar low thrombogenicity [11]. Patients did not
change the membrane during the study. Two needles were
used for vascular access in all patients. Blood flow was be-
tween 250 and 300 mL/min. Individual blood flow did not
change during the observation periods. The dialysate flow
was ≥500 mL/min in all patients. None of the patients re-
ceived any additional infusions during hemodialysis.
Blood sampling
At each dialysis session samples for the blood val-
ues were drawn from the arterial line predialysis, after
2 hours and 1 to 5 minutes after the end of the treatment.
Blood analysis was performed after each treatment ses-
sion. Hemostatic parameters included INR, prothrom-
bin time, anti-FXa activity, D-dimer, and fibrinogen. In
addition, white cell count, platelets, hemoglobin, hema-
tocrit, blood urea nitrogen (BUN), and creatinine were
measured. The decrease of white blood cells and throm-
bocytes was used to quantify the biocompatibility of the
dialyser membrane. For all tests, including the coagula-
tion studies, measurements where done using routinely
applied assays.
Dialysis efficiency
Efficacy of hemodialysis was assessed by calculation
of the Kt/V [Kt/V = −ln (R − 0.03) + [(4 − 3.5 × R)
× (UF ÷ W)] where R is postdialysis BUN/predialysis
BUN, UF is ultrafiltration, and W is postdialysis body
weight [12] and the urea reduction rate (URR = 1 − R).
Clotting in the dialyser and the air traps was estimated
visually using a scale from 0 to 4 (modified from Janssen et
al [13]). Grade 0 was equal to no detectable clotting, grade
1 to minimal clot formation, grade 2 to moderate clot
formation, grade 3 to major clots but dialysis still possible,
and grade 4 to complete occlusion of air traps or dialyzer.
In addition, the time of manual pressure on the shunt
puncture sites (SPT) after dialysis was recorded. The sites
were inspected after 5 minutes and then approximately
every 2 minutes until bleeding had stopped.
Statistical analysis
Values are given as median and range or mean ± SD,
as appropriate. The changes () of serologic markers be-
tween the two time periods (i.e., D-dimer, fibrinogen,
white blood cells, platelet) were compared by a
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Fig. 1. Anti-Xa serum levels (IU/mL) during hemodialysis with a dal-
teparin bolus injection of 40 IU/kg body weight at the beginning of
treatment.
mixed model (general linear model with fixed effects
and patients as a random effect). A similar model was
used for the comparison of the extent of coagulation in
the air traps and dialyser during each observation pe-
riod. The correlation between the changes of the sero-
logic markers and the extent of coagulation was calcu-
lated with Spearman’s correlation coefficient. The INR,
hemoglobin, body weight, ultrafiltration, absolute values
of D-dimer and bleeding time were compared between
the groups by the paired t test. A P value <0.05 was con-
sidered to be statistically significant.
RESULTS
The mean ± SD age of the patients (seven male and
three female) was 60.5 ± 6 years. The median (range)
INR was between 2 to 3 in all patients [phenprocoumon
2.2 (2 to 3) and dalteparin 2.1 (2 to 2.9)]. The median
anti-Xa level in patients receiving dalteparin in addition
to phenprocoumon was 0.33 (0.27 to 0.38) IU/mL after
2 hours and 0.16 (0.03 to 0.23) IU/mL after 4 hours of
therapy (Fig. 1). The median body weight [73 (62 to 94)
kg vs. 73 (61 to 99) kg] and median ultrafiltration volume
[2.6 (0.6 to 3.3) l vs. 2.3 (0.8 to 3.3) l] did not differ between
the observation periods.
The increase of D-dimer plasma level (D-dimer) was
significant in phenprocoumon patients but not in dal-
teparin (Table 1). The difference of the mean D-dimer
level at the beginning and the end of dialysis was sig-
nificant in the phenprocoumon patients (0.51 ± 0.30 vs.
0.87 ± 0.40 lg/mL) (P = 0.002) but not the dalteparin
patients (0.53 ± 0.20 vs. 0.67 ± 0.40 lg/mL) (P = 0.18).
The D-dimer serum values did not differ between phen-
procoumon and dalteparin at the beginning of the treat-
ment but showed a significant difference at the end of
dialysis (P = 0.02). The normal level of D-dimer is be-
low 0.5 lg/mL. The decrease of platelets was slightly, but
not significant, more pronounced in patients without ad-
ditional dalteparin. Changes of white blood cells and fib-
rinogen did not differ between the two groups (Table 1).
Hemoglobin concentrations at the beginning of each of
the three dialysis sessions during phenprocoumon were
not different to the corresponding sessions during dal-
teparin. Median (range) hemoglobin level of all three
sessions during phenprocoumon was 11.7 (8.5 to 13.8)
g/dL and during dalteparin 12.2 (8.1 to 15.2) g/dL (P =
0.51).
The extent of coagulation in the venous and arterial air
trap and the dialyser was significantly higher in patients
without additional dalteparin (Table 2). There was a sig-
nificant correlation between D-dimer and the extent of
coagulation in the venous air trap (r = 0.39, P = 0.03) in
phenprocoumon, and a significant correlation between
D-dimer and extent of coagulation in the dialyser in
dalteparin (r = 0.38, P = 0.04). In accordance, the de-
crease of thrombocytes correlated significantly with the
extent of thrombosis in the venous air trap (r= −0.46,
P = 0.009) in phenprocoumon, and with thrombosis in
the dialyser in dalteparin (r= −0.43, P = 0.016).
In the one patient with complete dialyser occlusion dur-
ing treatment without dalteparin the membrane used was
a polysulfone membrane. The cause for oral anticoag-
ulation was atrial fibrillation with an INR in the lower
range (2.1). The only differing value was a higher than
usual D-dimer at the beginning of dialysis (0.86 lg/mL).
This might hint at a higher thrombogenic state of this
patient.
The time of manual pressure on the shunt puncture
site was shorter in patients without dalteparin, but the
difference did not reach statistical significance [10 (5 to
20) min vs. 10 (5 to 60) min] (P = 0.057). The patients had
a similar weekly Kt/V during both observation periods
[phenprocoumon 3.6 (2.3 to 4.4) vs. dalteparin 3.7 (3.33
to 4.53)] (P = 0.11), and URR [0.63 (0.33 to 1.0) vs. 0.65
(0.51 to 0.78)] (P = 0.15).
DISCUSSION
This prospective study shows that oral anticoagulation
with a median INR of 2.2 (range 2 to 3) will not sufficiently
prevent clotting during hemodialysis. However, although
additional administration of a LMWH or heparin will be
necessary, its dose can be reduced to approximately 50%
of that usually applied.
The lack of sufficient anticoagulation without addi-
tional LMWH was demonstrated by an increase of the D-
dimer plasma level and increased clotting in the extracor-
poreal circuit. D-dimers are products of fibrin hydrolysis
and usually measured in patients with suspected deep ve-
nous thrombosis or pulmonary emboli but can be used as
a general marker for thrombus formation. The D-dimer
serum concentration has been shown to correlate closely
to thrombin-antithrombin complex formation, and thus
coagulation, during hemodialysis in acute renal failure
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Table 1. Changes of serologic parameters during hemodialysis with and without additional dalteparin therapy (statistical analysis by a mixed
model)
Phenprocoumon Phenprocoumon + dalteparin
Median (range) Median (range) P value
D-dimer lg/mL 0.23 (−0.24–1.35) 0.03 (−0.16–1.21) 0.0004
White blood cells 109/L −0.60 (−1.80–0.60) −0.60 (−2.00–0.90) 0.70
Platelet 109/L −8.0 (−60–16) 0.50 (−11–31) 0.10
Fibrinogen g/L 0.055 (−0.58–70) 0.14 (−2.96–58) 0.60
Table 2. Median differences of clot formation at the end of dialysis in the arterial and venous air trap and the dialyser in patients with and
without additional dalteparin
Phenprocoumon Phenprocoumon + dalteparin
Median (range) Median (range) P value
Arterial air trap 1 (0–2) 0 (0–1) 0.0014
Venous air trap 1 (0–3) 0 (0–1) 0.0002
Dialyser 2 (1–4) 1 (1–3) 0.0005
Abbreviations are: 0, no detectable clotting; 1, minimal clot formation; 2, moderate clot formation; 3, major clots but dialysis still possible; and 4, complete occlusion.
Calculation was performed by a mixed model which compared the values of 30 measurements (10 patients with three treatment sessions) from each group.
[14]. We found a similar close correlation to prothrombin
fragment 1 + 2 formation in patients with chronic renal
failure and maintenance dialysis at our dialysis unit (data
not shown). However, since thrombin-antithrombin com-
plex and prothombin fragment 1 + 2 is lowered in patients
with oral anticoagulants these markers could not be used
in this study. The sensitivity of D-dimer as a marker for
coagulation activity was instead demonstrated by a sig-
nificant correlation between clotting in parts of the ex-
tracorporeal circuit and the increase of D-dimer. Thus,
its measurement might generally be useful for the esti-
mation of anticoagulation during hemodialysis.
The stronger activation of coagulation in patients with-
out additional dalteparin was also demonstrated by a
greater extent of air trap and dialyzer occlusion in this
group. The main degree of thrombus formation was no-
ticed in the membrane followed by the venous and ar-
terial air trap, which probably can be explained by the
large thrombogenic surface of the membrane and hemo-
concentration during ultrafiltration.
Although patients without additional dalteparin had
a slightly lower Kt/V and URR the difference was not
significant. This was probably related to a statistical b
error based on the low number of patients included and
the short observation period. Repeated thrombosis of the
extracorporeal circuit will, over the long run, most likely
reduce the overall dialysis dose, and thus Kt/V, to a sig-
nificant extent.
Among others Sagedal et al have demonstrated the ef-
ficacy of a single dose of dalteparin to prevent clotting
during a 4-hour dialysis session [10, 15]. The antifactor
Xa serum level should be above 0.4 IU/mL at the end of
dialysis which reduces the risk of clotting events to almost
zero. This was achieved with a dalteparin dose of approxi-
mately 70 IU/kg. The authors also investigated the effect
of a decreased dalteparin dose (mean 61 IU/kg) in pa-
tients receiving warfarin. Although the anti-Xa level at
the end of dialysis was in the lowest detection level these
patients had a significantly lower activation of the co-
agulation markers thrombin-antithrombin complex and
prothrombin fragment 1 + 2 compared to patients with-
out warfarin. Since thrombin-antithrombin complex and
prothrombin fragment 1 + 2 levels might be influenced by
oral anticoagulants these results have to be interpreted
cautiously, but nevertheless indicate that the adminis-
tered LMWH dose can be reduced in patients receiving
warfarin or phenprocoumon. However, in this study the
lower dalteparin doses in warfarin-treated patients dif-
fered widely. Furthermore, the study did not investigate
the possibility to completely abolish additional anticoag-
ulation.
Although a mean anti-Xa serum level of 0.4 IU/mL
at the end of dialysis was achieved by a dalteparin dose
of only 39 IU/kg body weight in one study [16] the low
dose regimen of 40 IU/kg body weight in our patients led
to a median anti-Xa level of 0.15 IU/mL after 4 hours
and was below 0.4 IU/mL in nine out of ten patients.
These differing results hint at a different response of in-
dividual patients to the same dose of dalteparin. In order
to avoid overanticoagulation during hemodialysis in pa-
tients already treated with oral anticoagulants, the dose
administered should therefore rather be adjusted to the
anti-Xa level at the end of dialysis (which should be ap-
proximately 0.15 IU/mL), or to changes of D-dimer level,
than to the body weight.
CONCLUSION
We were able to demonstrate that standard oral anti-
coagulation (INR between 2 and 3) alone will not pre-
vent clotting during dialysis. Additional administration
of a fractionated or unfractionated heparin is necessary,
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but the dose can be reduced by at least 50%. It remains
unclear, however, whether this also includes patients
treated with a more intensive regimen reaching an INR of
3 to 3.5, which, for example, is recommended after mitral
valve replacement.
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